The Ubiquitin System in Cancer

Last May, the US Food and Drug Administration approved the first weapon in what could become a brand new arsenal against cancer. That weapon is Velcade (bortezomib), a drug that inhibits an intracellular protein-disposal system known as ubiquitin-mediated proteolysis (UMP). Made by Cambridge, Mass.-based Millennium Pharmaceuticals, Velcade improves and prolongs the lives of some patients with relapsed and refractory multiple myeloma. As a succession of companies tested Velcade (also called P

| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Last May, the US Food and Drug Administration approved the first weapon in what could become a brand new arsenal against cancer. That weapon is Velcade (bortezomib), a drug that inhibits an intracellular protein-disposal system known as ubiquitin-mediated proteolysis (UMP). Made by Cambridge, Mass.-based Millennium Pharmaceuticals, Velcade improves and prolongs the lives of some patients with relapsed and refractory multiple myeloma.

As a succession of companies tested Velcade (also called PS-341) over the past eight years, this boronic acid compound aroused skepticism and puzzlement. Besides oncogenic proteins, "there are numerous other proteins whose degradation is controlled by the [UMP] pathway," says I. Bernard Weinstein, professor of medicine at Columbia University. "So it's not intuitively obvious that this would be a mechanism that you'd want to target."

Julian Adams, head of the team that discovered Velcade, confesses: "I wasn't surprised it had an effect on cancer. My surprise--and what took me ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Douglas Steinberg

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide